Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors

Cellular and Molecular Life Sciences(2024)10.1007/s00018-024-05280-6Source: DataRank Database

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors is a research paper published in Cellular and Molecular Life Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.02)OA: goldTopics (63)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Guanjie Wang ORCID,Juan Liu ORCID,Mengmeng Yuan,Pu Chen ORCID,Yao Yao ORCID

Live enrichment

PubMed:38795180 OpenAlex:https://openalex.org/W4399021867

National Natural Science Foundation of China

Grant: 82072949

FWCI

1.02

Citation Percentile

0.8%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.1007/s00018-024-05280-6

publisherhttps://doi.org/10.1007/s00018-024-05280-6

publisherhttps://link.springer.com/content/pdf/10.1007/s00018-024-05280-6.pdf

publisherhttps://link.springer.com/article/10.1007/s00018-024-05280-6/fulltext.html

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38795180

Fields of Study

Thyroid Cancer Diagnosis and TreatmentS100 Proteins and AnnexinsCancer-related Molecular PathwaysProto-Oncogene Proteins B-rafHumansAnimalsThyroid NeoplasmsIndolesMiceDrug Resistance, NeoplasmSulfonamidesProtein Kinase InhibitorsCell Line, TumorPhenylurea CompoundsSorafenibQuinolinesMutationAntigensProteoglycansMembrane ProteinsChondroitin Sulfate ProteoglycansChondroitin Sulfate Proteoglycan 4

MeSH Terms

SorafenibChondroitin Sulfate Proteoglycan 4AnimalsAntigensHumansIndolesMembrane ProteinsMutationPhenylurea CompoundsChondroitin Sulfate ProteoglycansProteoglycansQuinolinesSulfonamidesThyroid NeoplasmsDrug Resistance, NeoplasmCell Line, TumorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafMice

Keywords

Cancer researchThyroid cancerLenvatinibMEK inhibitorSorafenibV600EPapillary thyroid cancerCancerReceptor tyrosine kinaseKinaseTargeted therapyBiologyMedicineMAPK/ERK pathwayMutantInternal medicineCell biologyGeneticsBRAF mutationsFeedback activationNG2Receptor tyrosine kinase (RTK)

Sustainable Development Goals

SDG 0: Good health and well-being